Back to News
Market Impact: 0.4
Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Alnylam Pharmaceuticals reported global net product revenues of $1.292 billion for the third quarter ended September 30, 2026, up 52% from Q3 2025. The article excerpt does not provide further details on the growth drivers or comparisons with expectations.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment
ALNY0.60
More News
- DoorDash offers $17 billion for Instacart: ‘the largest companies are only eating more and more of the pie’
- Alphabet Erases $500 Billion as ChatGPT, Google AI Cut into Search
- Alphabet just had its worst day as a public company. BofA now values Google search at a lower multiple than fossil fuel stocks
- Norwegian shares surge 13% on earnings beat, guidance raise
- Taiwan Stocks Heads for Correction as Global AI Selloff Deepens
- Asia stocks tumble as AI spending concerns deepen; BOJ holds rates